Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Projected to Have ACA to Thank for Growth - Assuming it Remains As-Is

This article was originally published in RPM Report

Executive Summary

The Centers for Medicare and Medicaid’s Office of the Actuary projects that aggregate health care spending will grow modestly - then spike in 2014. That’s due to coverage expansions in the Affordable Care Act, and pharma stands to get among the biggest gains. The June report release means industry would have at least a couple weeks to enjoy the projections before they potentially no longer apply.

You may also be interested in...

Antibiotic Payment Incentives: Advocates Still Looking For More

After some success in enacting new regulatory and exclusivity incentives in the US over the past decade, antibiotic research advocates are urging action on the payment/reimbursement side. One start-up CEO argues that Medicare needs to rethink its approach to payment for hospital antibiotics.

Diversity Plans For US FDA: Oncology Experience Will Inform New Policies

US FDA will be transitioning from the ‘diversity plans’ outlined in recent guidance to the new, legislatively directed ‘diversity action plans’ by the end of 2023. The oncology group is leading the way in gathering early perspectives on industry approaches.

US FDA Outlines Psychedelic Drug Trial Principles, But It Won’t Be An Easy Trip

The US FDA is offering its first formal advice for potential approaches to develop psychedelic drugs for therapeutic indications. But it won’t be easy.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts